<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy</h1>

    <table>
      <tr><th>Ticker</th><td>DTIL</td></tr>
      <tr><th>Float</th><td>19.0 M</td></tr>
      <tr><th>IO</th><td>39.54%</td></tr>
      <tr><th>MC</th><td>90.5 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Precision BioSciences (NASDAQ: DTIL) announced the FDA issued a Study May Proceed notification for its IND for PBGENE-DMD, allowing IRB review and clinical site activation for the Phase 1/2 FUNCTION-DMD trial. PBGENE-DMD is a first-in-class in vivo gene editing therapy using an ARCUS-based gene excision approach targeting DMD mutations in exons 45-55 (≈60% of patients) to restore a near full-length dystrophin (~80% of full length). The company plans U.S. site activation in H1 2026, expects initial patient data by year-end 2026, and has received FDA Rare Pediatric Disease and Orphan Drug designations. A virtual investor event is planned in March following the Muscular Dystrophy Association meeting.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>FDA Study May Proceed notification received, enabling IRB activities and site activation</li><li>Therapy targets mutations in exons 45–55, covering ~60% of DMD patients</li><li>Design aims to restore near full-length dystrophin (~80% of full length) versus smaller micro-dystrophin constructs</li><li>Has FDA Rare Pediatric Disease and Orphan Drug designations</li><li>Company provided a near-term operational timeline (site activation in H1 2026; initial data by year-end 2026)</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Program is entering first-in-human Phase 1/2 trials; clinical safety and efficacy are unproven</li><li>Clinical timelines and outcomes are forward-looking and subject to regulatory and IRB processes</li><li>Therapy requires immune modulation and monitoring, adding complexity to development and administration</li><li>Initial efficacy readouts depend on biopsy-based dystrophin expression and limited early patient cohorts</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/7f821c21-9da7-4a35-a867-100203698334" target="_blank">Original Article</a>
    </div>

    <div class="small">DTIL • TradersLink AI News</div>
  </div>
</body>
</html>